What is the efficacy of Truvada (tenofovir disoproxil fumarate + emtricitabine) as pre‑exposure prophylaxis, and how soon after the first dose does protective effect begin?

Truvada Efficacy and Time to Protection

For men who have sex with men (MSM), Truvada provides maximal protection within 24 hours when initiated with a double dose (2 tablets) followed by daily dosing; for all other populations including women, maximal protection requires approximately 7 days of daily dosing. 1

Efficacy Overview

Truvada (tenofovir disoproxil fumarate/emtricitabine) demonstrates >90% efficacy for HIV prevention when adherence is high, with effectiveness directly correlated to the number of doses taken per week 2, 3:

• Daily dosing (7 doses/week): Provides maximal protection with near-zero HIV incidence 4
• 4-6 doses/week: Maintains high-level protection (79-88% reduction for rectal exposures) 2
• 2+ doses/week: Estimated 79-88% reduction for rectal exposures 2
• <2 doses/week: Substantially reduced efficacy 4

The most recent pooled analysis of 6,296 cisgender women showed overall HIV incidence of only 0.72 per 100 person-years, with zero infections among those with consistently daily adherence and only 1 infection among 658 women with consistently high adherence (4-6 doses/week) 4.

Time to Protective Effect: Population-Specific

For MSM and Transgender Women Having Receptive Anal Sex

The 2025 IAS-USA guidelines recommend initiating with a double dose (2 tablets) of TDF/FTC on day 1, followed by single daily dosing thereafter. This achieves maximal protection within 24 hours of the double dose 1. This rapid onset is supported by pharmacokinetic data showing adequate tissue drug concentrations are achieved quickly in rectal tissue 2.

Critical timing detail: When discontinuing, continue dosing for 2 days after the last receptive anal exposure 2, 1.

For Cisgender Women and Others with Vaginal/Neovaginal Exposures

Protection requires approximately 7 days of daily dosing to achieve maximal efficacy 1. The same double-dose initiation strategy is recommended, but the longer time to protection reflects slower drug accumulation in vaginal tissues compared to rectal tissues 2.

Critical timing detail: When discontinuing, continue dosing for at least 7 days after the last vaginal exposure 2, 1.

For Injection Drug Use

Daily TDF/FTC is recommended, with the 7-day timeline to maximal protection applying 2.

On-Demand (2-1-1) Dosing for MSM

An alternative for MSM with planned receptive anal sex is the 2-1-1 regimen 2, 1:

• 2 tablets: 2-24 hours before sex
• 1 tablet: 24 hours after first dose
• 1 tablet: 48 hours after first dose

This provides approximately 86% efficacy when used correctly 1. However, this regimen is only validated for MSM with receptive anal exposure—insufficient data exist for vaginal exposures or injection drug use 2, 1.

Important caveat for transgender women on hormone therapy: Take 2-1-1 doses with food, as rectal tissue drug concentrations may be lower early in the regimen, which food intake can mitigate 2.

Common Pitfalls to Avoid

1. Starting PrEP without confirming HIV-negative status: Always confirm negative HIV test immediately before initiating. If acute HIV symptoms are present with recent exposure (<1 month), delay PrEP for at least 1 month and reconfirm status 5

2. Assuming immediate protection: The 24-hour protection window applies only to MSM with the double-dose initiation. All other populations need 7 days 1

3. Stopping too early after last exposure: Rectal exposures require 2 additional days of dosing; vaginal exposures require 7 additional days 2, 1

4. Using on-demand dosing for women: The 2-1-1 regimen is not validated for vaginal exposures and should not be used 2, 1

5. Prescribing without renal assessment: Do not use Truvada for PrEP if creatinine clearance is <60 mL/min 5

Monitoring Requirements

• HIV testing every 3 months while on PrEP 5
• Renal function monitoring in all patients, especially those with baseline CrCl 50-80 mL/min 5
• STI screening should continue as rates remain high (21-28 cases per 100 person-years for rectal gonorrhea/chlamydia) 6

The evidence strongly supports that Truvada is highly effective when taken as prescribed, but the timing to protection and continuation after exposure must be tailored to the specific route of HIV exposure 2, 1.